RU2012106200A - Агонисты рецептора глюкагоноподобного пептида-1 (glp-1r) для лечения аутоиммунных расстройств - Google Patents
Агонисты рецептора глюкагоноподобного пептида-1 (glp-1r) для лечения аутоиммунных расстройств Download PDFInfo
- Publication number
- RU2012106200A RU2012106200A RU2012106200/15A RU2012106200A RU2012106200A RU 2012106200 A RU2012106200 A RU 2012106200A RU 2012106200/15 A RU2012106200/15 A RU 2012106200/15A RU 2012106200 A RU2012106200 A RU 2012106200A RU 2012106200 A RU2012106200 A RU 2012106200A
- Authority
- RU
- Russia
- Prior art keywords
- glp
- agonist
- absent
- antibody
- peptide
- Prior art date
Links
- 208000023275 Autoimmune disease Diseases 0.000 title claims abstract 7
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 title claims abstract 7
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 title claims abstract 7
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 title 1
- 101800000224 Glucagon-like peptide 1 Proteins 0.000 title 1
- 102100040918 Pro-glucagon Human genes 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 238000000034 method Methods 0.000 claims abstract 26
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 claims abstract 20
- GNZCSGYHILBXLL-UHFFFAOYSA-N n-tert-butyl-6,7-dichloro-3-methylsulfonylquinoxalin-2-amine Chemical compound ClC1=C(Cl)C=C2N=C(S(C)(=O)=O)C(NC(C)(C)C)=NC2=C1 GNZCSGYHILBXLL-UHFFFAOYSA-N 0.000 claims abstract 12
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 claims abstract 8
- 241000124008 Mammalia Species 0.000 claims abstract 6
- 210000003169 central nervous system Anatomy 0.000 claims abstract 4
- JUFFVKRROAPVBI-PVOYSMBESA-N chembl1210015 Chemical group C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N[C@H]1[C@@H]([C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@]3(O[C@@H](C[C@H](O)[C@H](O)CO)[C@H](NC(C)=O)[C@@H](O)C3)C(O)=O)O2)O)[C@@H](CO)O1)NC(C)=O)C(=O)NCC(=O)NCC(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CO)C(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 JUFFVKRROAPVBI-PVOYSMBESA-N 0.000 claims abstract 4
- 230000009545 invasion Effects 0.000 claims abstract 4
- 210000000265 leukocyte Anatomy 0.000 claims abstract 4
- 230000003287 optical effect Effects 0.000 claims abstract 4
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 4
- 102000016622 Dipeptidyl Peptidase 4 Human genes 0.000 claims abstract 3
- 108010067722 Dipeptidyl Peptidase 4 Proteins 0.000 claims abstract 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims abstract 2
- 208000003807 Graves Disease Diseases 0.000 claims abstract 2
- 208000015023 Graves' disease Diseases 0.000 claims abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims abstract 2
- 206010029240 Neuritis Diseases 0.000 claims abstract 2
- 206010046851 Uveitis Diseases 0.000 claims abstract 2
- 239000000556 agonist Substances 0.000 claims abstract 2
- 208000024908 graft versus host disease Diseases 0.000 claims abstract 2
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract 2
- 206010028417 myasthenia gravis Diseases 0.000 claims abstract 2
- 201000001119 neuropathy Diseases 0.000 claims abstract 2
- 230000007823 neuropathy Effects 0.000 claims abstract 2
- 206010039073 rheumatoid arthritis Diseases 0.000 claims abstract 2
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims abstract 2
- 208000009174 transverse myelitis Diseases 0.000 claims abstract 2
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 claims 2
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 claims 2
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 claims 2
- 229960003104 ornithine Drugs 0.000 claims 2
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 claims 1
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-UWTATZPHSA-N D-alanine Chemical compound C[C@@H](N)C(O)=O QNAYBMKLOCPYGJ-UWTATZPHSA-N 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 claims 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 229940127104 WYE-155189 Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000000903 blocking effect Effects 0.000 claims 1
- 150000001720 carbohydrates Chemical class 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229940090124 dipeptidyl peptidase 4 (dpp-4) inhibitors for blood glucose lowering Drugs 0.000 claims 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 1
- 230000000269 nucleophilic effect Effects 0.000 claims 1
- GVNVAWHJIKLAGL-UHFFFAOYSA-N 2-(cyclohexen-1-yl)cyclohexan-1-one Chemical compound O=C1CCCCC1C1=CCCCC1 GVNVAWHJIKLAGL-UHFFFAOYSA-N 0.000 abstract 1
- 101150065749 Churc1 gene Proteins 0.000 abstract 1
- 102100038239 Protein Churchill Human genes 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Vascular Medicine (AREA)
- Cell Biology (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23765409P | 2009-08-27 | 2009-08-27 | |
| US61/237,654 | 2009-08-27 | ||
| PCT/IB2010/053754 WO2011024110A2 (en) | 2009-08-27 | 2010-08-19 | Glucagon-like peptide-1 receptor (glp-1r) agonists for treating autoimmune disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2012106200A true RU2012106200A (ru) | 2013-10-10 |
Family
ID=43384669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2012106200/15A RU2012106200A (ru) | 2009-08-27 | 2010-08-19 | Агонисты рецептора глюкагоноподобного пептида-1 (glp-1r) для лечения аутоиммунных расстройств |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20120148586A1 (OSRAM) |
| EP (1) | EP2470198A2 (OSRAM) |
| JP (1) | JP2011057670A (OSRAM) |
| KR (1) | KR20120050460A (OSRAM) |
| CN (1) | CN102596229A (OSRAM) |
| AU (1) | AU2010288191A1 (OSRAM) |
| BR (1) | BR112012004043A2 (OSRAM) |
| CA (1) | CA2769835A1 (OSRAM) |
| IL (1) | IL217967A0 (OSRAM) |
| IN (1) | IN2012DN00961A (OSRAM) |
| MX (1) | MX2012002463A (OSRAM) |
| RU (1) | RU2012106200A (OSRAM) |
| WO (1) | WO2011024110A2 (OSRAM) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2012356219B2 (en) * | 2011-12-22 | 2016-03-31 | Covx Technologies Ireland Limited | Anti-diabetic compounds |
| SG11201407860PA (en) | 2012-06-14 | 2014-12-30 | Sanofi Sa | Exendin-4 peptide analogues |
| UA116217C2 (uk) * | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| US20140107028A1 (en) * | 2012-10-15 | 2014-04-17 | The University Of Chicago | Methods and compositions for predicting response to glp-1 analogs |
| JP2016506401A (ja) | 2012-12-21 | 2016-03-03 | サノフイ | 二重ｇｌｐ１／ｇｉｐまたは三方ｇｌｐ１／ｇｉｐ／グルカゴンアゴニストとしてのエキセンジン−４誘導体 |
| US20160082137A1 (en) * | 2013-07-25 | 2016-03-24 | Sloan-Kettering Institute For Cancer Research | Clinical Multimodality-Tools for Pre-And Intraoperative Insulinoma Diagnostics |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| WO2015086731A1 (en) * | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/glucagon receptor agonists |
| TW201609799A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 雙重ｇｌｐ－１／ｇｉｐ受體促效劑 |
| TW201609796A (zh) | 2013-12-13 | 2016-03-16 | 賽諾菲公司 | 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物 |
| EP3080150B1 (en) | 2013-12-13 | 2018-08-01 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| AR098614A1 (es) * | 2013-12-18 | 2016-06-01 | Lilly Co Eli | Compuesto para el tratamiento de hipoglicemia severa |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| US12098202B2 (en) * | 2016-10-10 | 2024-09-24 | The National Institute for Biotechnology in the Negev Ltd. | Non-cytotoxic modified cells and use thereof |
| WO2018078112A1 (en) * | 2016-10-27 | 2018-05-03 | Aarhus Universitet | Glp-1 agonist (eg liraglutide) for use in the treatment of multiple sclerosis |
| AR110300A1 (es) * | 2016-12-02 | 2019-03-13 | Sanofi Sa | Compuestos como agonistas peptídicos trigonales de los receptores de glp1 / glucagón / gip |
| WO2018226590A1 (en) * | 2017-06-05 | 2018-12-13 | The Trustees Of Columbia University In The City Of New York | Peptides as biomarkers in the diagnosis, confirmation and treatment of a neurological disorder and immunoprofiling in neurodegenerative disease |
| JP7239566B2 (ja) | 2017-09-22 | 2023-03-14 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | グルカゴン様ペプチド１受容体アゴニストおよびそれらの使用 |
| AU2019237507B2 (en) | 2018-03-23 | 2025-04-03 | Carmot Therapeutics, Inc. | Modulators of G-protein coupled receptors |
| PE20231066A1 (es) | 2020-02-07 | 2023-07-17 | Gasherbrum Bio Inc | Agonistas heterociclicos de glp-1 |
| EP4143183B1 (en) | 2020-04-29 | 2025-10-22 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| MX2023002974A (es) * | 2020-09-14 | 2023-05-25 | Regeneron Pharma | Conjugados de anticuerpo-farmaco que comprenden peptidomimeticos glp1 y usos de los mismos. |
| EP4334304A1 (en) | 2021-05-03 | 2024-03-13 | Carmot Therapeutics, Inc. | Benzimidazoyl glp-1 receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| IL308392A (en) | 2021-05-13 | 2024-01-01 | Carmot Therapeutics Inc | G protein-coupled receptor modulators |
| JP2025509281A (ja) | 2022-03-09 | 2025-04-11 | ガシャーブラム・バイオ・インコーポレイテッド | ヘテロ環式ｇｌｐ－１アゴニスト |
| AU2023231305A1 (en) * | 2022-03-11 | 2024-09-12 | Regeneron Pharmaceuticals, Inc. | Anti-GLP1r antibody-tethered drug conjugates comprising GLP1 peptidomimetics and uses thereof |
| EP4496797A1 (en) | 2022-03-21 | 2025-01-29 | Gasherbrum Bio, Inc. | 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes |
| EP4508047A1 (en) | 2022-04-14 | 2025-02-19 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2024026338A1 (en) | 2022-07-27 | 2024-02-01 | Carmot Therapeutics, Inc. | N-heterocylic gpcr receptor agonists, pharmaceutical compositions comprising the same, and methods for their use |
| KR20250075642A (ko) | 2022-09-21 | 2025-05-28 | 리제너론 파아마슈티컬스, 인크. | 비만, 당뇨병 및 간 기능 장애를 치료하는 방법 |
| KR20250157491A (ko) | 2022-12-15 | 2025-11-04 | 가셔브룸 바이오, 인크. | Glp-1 효능제 활성을 갖는 화합물의 염 및 고체 형태 |
| EP4638440A1 (en) | 2022-12-22 | 2025-10-29 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| CN120693338A (zh) | 2022-12-22 | 2025-09-23 | 加舒布鲁姆生物公司 | 杂环的glp-1激动剂 |
| IL322686A (en) | 2023-02-16 | 2025-10-01 | Gasherbrum Bio Inc | Heterocyclic glp-1 agonists |
| CN121773120A (zh) | 2023-06-30 | 2026-03-31 | 加舒布鲁姆生物公司 | 杂环glp-1激动剂 |
| EP4743174A1 (en) | 2023-07-13 | 2026-05-20 | Aconcagua Bio Inc | CALCITONIN AND/OR AMYLIN RECEPTOR ACTIVITY MODULATORS |
| AR133241A1 (es) | 2023-07-13 | 2025-09-10 | Aconcagua Bio Inc | Compuestos, composiciones y métodos |
| WO2025045208A1 (en) | 2023-08-31 | 2025-03-06 | Gasherbrum Bio, Inc. | Heteroaryl-heterocycloalkyl-based glp-1 agonists |
| WO2025137307A1 (en) | 2023-12-20 | 2025-06-26 | Gasherbrum Bio, Inc. | Heterocyclic glp-1 agonists |
| WO2025171341A2 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity |
| WO2025171340A1 (en) | 2024-02-08 | 2025-08-14 | Aconcagua Bio, Inc. | The treatment of calcitonin- and/or amylin-receptor associated conditions |
| WO2026041075A1 (en) | 2024-08-21 | 2026-02-26 | Gasherbrum Bio, Inc. | Gpl-1 agonists |
| WO2026096926A1 (en) | 2024-11-01 | 2026-05-07 | Aconcagua Bio, Inc. | Compounds, compositions, and methods |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4754065A (en) | 1984-12-18 | 1988-06-28 | Cetus Corporation | Precursor to nucleic acid probe |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US4800159A (en) | 1986-02-07 | 1989-01-24 | Cetus Corporation | Process for amplifying, detecting, and/or cloning nucleic acid sequences |
| DE69126871T2 (de) | 1990-04-06 | 1998-03-12 | Jolla Cancer Res Found | Verfahren und verbindung zur behandlung von thrombose |
| US5424286A (en) | 1993-05-24 | 1995-06-13 | Eng; John | Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same |
| US5733757A (en) | 1995-12-15 | 1998-03-31 | The Scripps Research Institute | Aldolase catalytic antibody |
| ES2237790T3 (es) | 1996-11-12 | 2005-08-01 | Novo Nordisk A/S | Uso de peptidos glp-1. |
| US6723530B1 (en) | 1997-02-05 | 2004-04-20 | Amylin Pharmaceuticals, Inc. | Polynucleotides encoding proexendin, and methods and uses thereof |
| US6326176B1 (en) | 1997-12-18 | 2001-12-04 | The Scripps Research Institute | Aldol condensations by catalytic antibodies |
| JP2003516121A (ja) | 1999-09-27 | 2003-05-13 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 不可逆的に結合するエンジニアリング抗体 |
| US6294374B1 (en) | 1999-10-08 | 2001-09-25 | The Scripps Research Institute | Use of catalytic antibodies for synthesizing epothilone |
| ATE385238T1 (de) * | 2001-06-27 | 2008-02-15 | Probiodrug Ag | Verwendung von dpiv-inhibitoren als therapeutika für krankhafte neurologische zustände |
| JP2005501058A (ja) | 2001-07-31 | 2005-01-13 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | Ｇｌｐ−１、ｅｘｅｎｄｉｎ−４、そのペプチド・アナログ及びその使用 |
| US20060205037A1 (en) | 2003-08-28 | 2006-09-14 | Homayoun Sadeghi | Modified transferrin fusion proteins |
| US20060275288A1 (en) * | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| KR101193722B1 (ko) | 2006-07-24 | 2013-01-11 | 바이오렉시스 파마슈티칼 코포레이션 | 엑센딘 융합 단백질 |
| TWI428346B (zh) | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| KR20090091181A (ko) | 2006-12-20 | 2009-08-26 | 리나트 뉴로사이언스 코퍼레이션 | 자가면역 장애의 치료를 위한 티로신 수용체 키나아제 ｂ 작용제 |
| US20090098130A1 (en) | 2007-01-05 | 2009-04-16 | Bradshaw Curt W | Glucagon-like protein-1 receptor (glp-1r) agonist compounds |
| WO2009030771A1 (en) * | 2007-09-05 | 2009-03-12 | Novo Nordisk A/S | Peptides derivatized with a-b-c-d- and their therapeutical use |
-
2009
- 2009-08-19 US US13/392,244 patent/US20120148586A1/en not_active Abandoned
-
2010
- 2010-08-19 BR BR112012004043A patent/BR112012004043A2/pt not_active IP Right Cessation
- 2010-08-19 RU RU2012106200/15A patent/RU2012106200A/ru not_active Application Discontinuation
- 2010-08-19 EP EP10754580A patent/EP2470198A2/en not_active Withdrawn
- 2010-08-19 CN CN2010800481995A patent/CN102596229A/zh active Pending
- 2010-08-19 CA CA2769835A patent/CA2769835A1/en not_active Abandoned
- 2010-08-19 KR KR1020127004905A patent/KR20120050460A/ko not_active Ceased
- 2010-08-19 MX MX2012002463A patent/MX2012002463A/es not_active Application Discontinuation
- 2010-08-19 WO PCT/IB2010/053754 patent/WO2011024110A2/en not_active Ceased
- 2010-08-19 AU AU2010288191A patent/AU2010288191A1/en not_active Abandoned
- 2010-08-19 IN IN961DEN2012 patent/IN2012DN00961A/en unknown
- 2010-08-26 JP JP2010189054A patent/JP2011057670A/ja not_active Withdrawn
-
2012
- 2012-02-06 IL IL217967A patent/IL217967A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2012002463A (es) | 2012-03-14 |
| JP2011057670A (ja) | 2011-03-24 |
| IL217967A0 (en) | 2012-03-29 |
| WO2011024110A3 (en) | 2011-04-21 |
| BR112012004043A2 (pt) | 2019-09-24 |
| CA2769835A1 (en) | 2011-03-03 |
| CN102596229A (zh) | 2012-07-18 |
| EP2470198A2 (en) | 2012-07-04 |
| US20120148586A1 (en) | 2012-06-14 |
| IN2012DN00961A (OSRAM) | 2015-04-10 |
| WO2011024110A2 (en) | 2011-03-03 |
| KR20120050460A (ko) | 2012-05-18 |
| AU2010288191A1 (en) | 2012-03-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12297286B2 (en) | Transferrin receptor (TFR)-selective binding peptides capable of crossing the blood brain barrier, encoding nucleic acids thereof and methods of use thereof | |
| JP6749235B2 (ja) | Ｇｌｐ−１ｒに特異的に結合する抗体およびそのｇｌｐ−１との融合タンパク質 | |
| EP2411412B1 (en) | Humanized antibodies against light and uses thereof | |
| US12589159B2 (en) | CD71 binding fibronectin type III domains | |
| RU2432361C2 (ru) | Соединения агонисты рецептора глюкагоноподобного белка-1 (glp-1r) | |
| JP2022541657A (ja) | インターロイキン－２作用物質およびその使用 | |
| CA2965560A1 (en) | Compositions and peptides having dual glp-1r and glp-2r agonist activity | |
| KR20170133458A (ko) | T 세포 면역글로불린 및 뮤신 단백질 3 (tim-3)에 대한 항체 | |
| KR20180069067A (ko) | 안티-ror1 항체 | |
| US20250161476A1 (en) | Antibody-drug conjugates comprising glp1 peptidomimetics and uses thereof | |
| CN103764677A (zh) | 抗神经生长因子抗体及其制备和使用方法 | |
| CN102740884A (zh) | 通过施用针对降钙素基因相关肽的拮抗性抗体来治疗内脏痛的方法 | |
| JP2024503506A (ja) | インターロイキン－２変異体およびその使用 | |
| JP2022548728A (ja) | 抗ｐｔｃｒａ抗体－薬物コンジュゲートおよびその使用 | |
| JP2024502708A (ja) | インターロイキン－２作用物質を使用する方法 | |
| US12037379B2 (en) | CD71 binding fibronectin type III domains | |
| ES2883377T3 (es) | Moleculas de unión a FGFR3 | |
| CN115052663A (zh) | Alk5抑制剂缀合物及其用途 | |
| JP2024542780A (ja) | 神経変性疾患の治療のためのペプチド薬物複合体 | |
| US20250171516A1 (en) | Peptide acids as a glp1r agonist and antibody-drug conjugates thereof | |
| KR20220140443A (ko) | 글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물 | |
| KR20220092446A (ko) | 단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 glp-2의 병용 요법 | |
| KR20210115239A (ko) | 신규 대사증후군 및 그와 관련된 질환 치료용 약학 조성물 | |
| US12491255B2 (en) | EPCAM binding fibronectin type III domains | |
| TW202547866A (zh) | Ｓｌｉｔｒｋ６結合劑、其共軛物及使用彼之方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20140526 |